News for Optimi Health Corp. (OPTHF)

Optimi Health (OTCQX: OPTHF) announces CAD$3.45 million convertible debenture financing at a 15% interest rate. Secured term loan of CAD$1 million exten

\n Optimi Health (OPTHF) has secured a U.S. FDA Establishment Identifier (FEI), allowing it to supply GMP-certified MDMA and psilocybin to the U.S. market.

Psychedelic-assisted therapy is on the rise, and a new report confirms the rate of expansion of the psychedelic mushrooms market.

**media[499532]**

U.S. futures declined on Friday, ahead of the 'Triple Witching' hour, which is expected to see $6.6 trillion options expire, for the quarter.

**media[488285]**

Optimi Health Corp. , a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to...

Canada Magic Mushrooms and MDMA market is hitting new milestones as canada has licensed Optimi to export psilocybin and MDMA to Australia

Canada has licensed Optimi Health to export psilocybin and MDMA to Australia, marking a significant step in the medical psychedelics market.

Optimi Health Awarded Drug Establishment Licence From Health Canada

Canada has licensed Optimi Health to export psychedelics to Australia, a milestone in the growth of medical psychedelic drugs. Read on.

Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research

VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed…

Three batches tested and validated by third-party laboratoryVANCOUVER, British Columbia, April 15, 2024 -- Optimi Health Corp. , a leading Health Canada licensed psychedelics pharmaceutical...

VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) —

Optimi CEO Bill Ciprick to speak on the future of GMP psychedelic manufacturing

First tranche of investment led by co-founders JJ Wilson and Dane StevensVANCOUVER, British Columbia, Feb. 28, 2024 -- Optimi Health Corp. , a Health Canada licensed drug researcher and...

Company shares behind-the-scenes look at its GMP MDMA encapsulation and production process

Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video Company shares behind-the-scenes look at its GMP MDMA encapsulation and production process GlobeNewswire February 12, 2024 VANCOUVER, British Columbia, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)...